L3VLUP
ProSign in

IRMD in the 13F filings

Iradimed Corp · CUSIP 46266A109

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 13 Nov 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 1 listed it in both
Shares listed
764,948
combined, among listed positions
Reported value
$34m
combined, at the quarter end

Managers listing IRMD in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Renaissance Technologies LLC574,912$26munder 0.1%Trimmedn.a.14 Nov 2023 (the filing on sec.gov)
Acadian Asset Management LLC181,783$8.1munder 0.1%Held013 Nov 2023 (the filing on sec.gov)
Winton Group Ltd8,253$366kunder 0.1%Newnew13 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q3 2024 to 2 in Q2 2026

Tracked managers listing it, at least.

01234201920222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
IRMD by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20171$171kn.a.n.a.
Q3 20181$611kn.a.n.a.
Q4 20181$213kn.a.n.a.
Q1 20191$244kn.a.n.a.
Q3 20211$1.1mn.a.n.a.
Q4 20211$32mn.a.n.a.
Q1 20221$6.4mn.a.n.a.
Q2 20221$5.6mn.a.n.a.
Q3 20221$5.0mn.a.n.a.
Q4 20221$4.7mn.a.n.a.
Q1 20231$7.1mn.a.n.a.
Q2 20231$8.7mn.a.n.a.
Q3 20233$34mn.a.n.a.
Q4 20233$36m21
Q1 20241$6.9m01
Q2 20241$6.3m01
Q3 20241$6.9m01
Q4 20241$7.8m10
Q1 20251$8.2m10
Q2 20252$11m11
Q3 20253$47m12
Q4 20253$62m138
Q1 20264$60m186
Q2 20262$38m816

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

IRMD and LLY →IRMD and JNJ →IRMD and VRTX →Choose a stock to compare with IRMD →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own IRMD, latest filings →Back to the 13F Explorer →